tiprankstipranks
Oncolytics Biotech (ONCY)
NASDAQ:ONCY
US Market
ONCY
Oncolytics Biotech
RESEARCH TOOLSreports
Want to see ONCY full AI Analyst Report?

Oncolytics Biotech (ONCY) Stock Forecast & Price Target

1,602 Followers
See the Price Targets and Ratings of:

ONCY Analyst Ratings

Strong Buy
4Ratings
Strong Buy
3 Buy
1 Hold
0 Sell
Based on 4 analysts giving stock ratings to
Oncolytics
Biotech
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

ONCY Stock 12 Month Forecast

Average Price Target

$6.00
▲(435.71% Upside)
Based on 4 Wall Street analysts offering 12 month price targets for Oncolytics Biotech in the last 3 months. The average price target is $6.00 with a high forecast of $10.00 and a low forecast of $3.00. The average price target represents a 435.71% change from the last price of $1.12.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"$2","5":"$5","8":"$8","11":"$11","-1":"-$1"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":10,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$10.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$6.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":3,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$3.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,2,5,8,11],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2025","6":"Dec<br/>2025","9":"Mar<br/>2026","12":"Jun<br/>2026","25":"Jun<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.06,1.7476923076923077,2.4353846153846153,3.123076923076923,3.8107692307692305,4.498461538461537,5.186153846153847,5.873846153846154,6.561538461538461,7.249230769230769,7.936923076923076,8.624615384615383,9.312307692307693,{"y":10,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.06,1.44,1.8199999999999998,2.2,2.58,2.96,3.34,3.7199999999999998,4.1,4.4799999999999995,4.859999999999999,5.24,5.619999999999999,{"y":6,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.06,1.2092307692307693,1.3584615384615386,1.5076923076923077,1.656923076923077,1.8061538461538462,1.9553846153846153,2.1046153846153848,2.253846153846154,2.403076923076923,2.5523076923076924,2.7015384615384614,2.850769230769231,{"y":3,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":0.344,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.75,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.99,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.15,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.42,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.19,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.94,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.874,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.968,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.02,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.93,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.87,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.06,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$10.00Average Price Target$6.00Lowest Price Target$3.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
JonesTrading Analyst forecast on ONCY
Boris Peaker
JonesTrading
JonesTrading
―
Hold
―
Reiterated
06/18/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Oncolytics Biotech (NASDAQ: ONCY), Stryker (NYSE: SYK) and Alkermes (NASDAQ: ALKS)
Lake Street Analyst forecast on ONCY
Chad Messer
Lake Street
Lake Street
$5
Buy
346.43%
Upside
Reiterated
06/01/26
Oncolytics Biotech (ONCY) Gets a Buy from Lake Street
H.C. Wainwright Analyst forecast on ONCY
Patrick Trucchio
H.C. Wainwright
H.C. Wainwright
$10
Buy
792.86%
Upside
Reiterated
05/29/26
Analysts Offer Insights on Healthcare Companies: CervoMed (NASDAQ: CRVO), Bicara Therapeutics Inc. (NASDAQ: BCAX) and Oncolytics Biotech (NASDAQ: ONCY)
Maxim Group Analyst forecast on ONCY
Jason McCarthy
Maxim Group
Maxim Group
$3
Buy
167.86%
Upside
Reiterated
05/21/26
Jason McCarthy Reiterates Buy Rating and Maintains $3 Price Target on Advancing Pelareorep Oncology Pipeline
Leede Financial Analyst forecast on ONCY
Douglas Loe
Leede Financial
Leede Financial
$4
Buy
257.14%
Upside
Reiterated
11/25/25
This Canadian biotech stock is tackling pancreatic CancerLeede Financial analyst Douglas Loe says recent feedback from the U.S. Food and Drug Administration gives Oncolytics Biotech (Oncolytics Biotech Stock Quote, Chart, News, Analysts, Financials TSX:ONC) a clear path into a pivotal trial for its oncolytic virus pelareorep in metastatic pancreatic cancer, but investors should still view it as a long-dated, high-risk story.
RBC Capital Analyst forecast on ONCY
Douglas Miehm
RBC Capital
RBC Capital
$3.5
Buy
212.50%
Upside
Reiterated
11/19/25
Oncolytics Biotech (ONCY) Gets a Buy from RBC Capital
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
JonesTrading Analyst forecast on ONCY
Boris Peaker
JonesTrading
JonesTrading
―
Hold
―
Reiterated
06/18/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Oncolytics Biotech (NASDAQ: ONCY), Stryker (NYSE: SYK) and Alkermes (NASDAQ: ALKS)
Lake Street Analyst forecast on ONCY
Chad Messer
Lake Street
Lake Street
$5
Buy
346.43%
Upside
Reiterated
06/01/26
Oncolytics Biotech (ONCY) Gets a Buy from Lake Street
H.C. Wainwright Analyst forecast on ONCY
Patrick Trucchio
H.C. Wainwright
H.C. Wainwright
$10
Buy
792.86%
Upside
Reiterated
05/29/26
Analysts Offer Insights on Healthcare Companies: CervoMed (NASDAQ: CRVO), Bicara Therapeutics Inc. (NASDAQ: BCAX) and Oncolytics Biotech (NASDAQ: ONCY)
Maxim Group Analyst forecast on ONCY
Jason McCarthy
Maxim Group
Maxim Group
$3
Buy
167.86%
Upside
Reiterated
05/21/26
Jason McCarthy Reiterates Buy Rating and Maintains $3 Price Target on Advancing Pelareorep Oncology Pipeline
Leede Financial Analyst forecast on ONCY
Douglas Loe
Leede Financial
Leede Financial
$4
Buy
257.14%
Upside
Reiterated
11/25/25
This Canadian biotech stock is tackling pancreatic CancerLeede Financial analyst Douglas Loe says recent feedback from the U.S. Food and Drug Administration gives Oncolytics Biotech (Oncolytics Biotech Stock Quote, Chart, News, Analysts, Financials TSX:ONC) a clear path into a pivotal trial for its oncolytic virus pelareorep in metastatic pancreatic cancer, but investors should still view it as a long-dated, high-risk story.
RBC Capital Analyst forecast on ONCY
Douglas Miehm
RBC Capital
RBC Capital
$3.5
Buy
212.50%
Upside
Reiterated
11/19/25
Oncolytics Biotech (ONCY) Gets a Buy from RBC Capital
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
TRAXFirst Tracks Biotherapeutics Inc
EVMNEvommune, Inc.
MPLTMapLight Therapeutics, Inc.
MAZEMaze Therapeutics, Inc.
AAPGAscentage Pharma Group International Unsponsored ADR
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Oncolytics Biotech

3 Months
Douglas MiehmRBC Capital
Success Rate
12/28 ratings generated profit
43%
Average Return
-0.81%
Copying Douglas Miehm's trades and holding each position for 3 Months would result in 42.86% of your transactions generating a profit, with an average return of -0.81% per trade.
1 Year
Patrick TrucchioH.C. Wainwright
Success Rate
9/18 ratings generated profit
50%
Average Return
+2.28%
Copying Patrick Trucchio's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +2.28% per trade.
2 Years
Patrick TrucchioH.C. Wainwright
Success Rate
7/18 ratings generated profit
39%
Average Return
+3.21%
Copying Patrick Trucchio's trades and holding each position for 2 Years would result in 38.89% of your transactions generating a profit, with an average return of +3.21% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ONCY Analyst Recommendation Trends

Rating
Feb 26
Mar 26
Apr 26
May 26
Jun 26
Strong Buy
11
9
8
8
9
Buy
0
0
0
0
0
Hold
0
0
2
2
4
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
11
9
10
10
13
In the current month, ONCY has received 9 Buy Ratings, 4 Hold Ratings, and 0 Sell Ratings. ONCY average Analyst price target in the past 3 months is 6.00.
Each month's total comprises the sum of three months' worth of ratings.

ONCY Financial Forecast

ONCY Earnings Forecast

Next quarter’s earnings estimate for ONCY is -$0.05 with a range of -$0.07 to -$0.04. The previous quarter’s EPS was -$0.08. ONCY beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year ONCY has Performed in-line its overall industry.
Next quarter’s earnings estimate for ONCY is -$0.05 with a range of -$0.07 to -$0.04. The previous quarter’s EPS was -$0.08. ONCY beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year ONCY has Performed in-line its overall industry.
No data currently available

ONCY Sales Forecast

Next quarter’s sales forecast for ONCY is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. ONCY beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year ONCY has Performed in-line its overall industry.
Next quarter’s sales forecast for ONCY is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. ONCY beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year ONCY has Performed in-line its overall industry.

ONCY Stock Forecast FAQ

What is ONCY’s average 12-month price target, according to analysts?
Based on analyst ratings, Oncolytics Biotech’s 12-month average price target is 6.00.
    What is ONCY’s upside potential, based on the analysts’ average price target?
    Oncolytics Biotech has 435.71% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is ONCY a Buy, Sell or Hold?
          Oncolytics Biotech has a consensus rating of Strong Buy which is based on 3 buy ratings, 1 hold ratings and 0 sell ratings.
            What is Oncolytics Biotech’s price target?
            The average price target for Oncolytics Biotech is 6.00. This is based on 4 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $10.00 ,the lowest forecast is $3.00. The average price target represents 435.71% Increase from the current price of $1.12.
              What do analysts say about Oncolytics Biotech?
              Oncolytics Biotech’s analyst rating consensus is a Strong Buy. This is based on the ratings of 4 Wall Streets Analysts.
                How can I buy shares of ONCY?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.